# Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

> **NCT01416974** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** modified T cells

## Key facts

- **NCT ID:** NCT01416974
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-22
- **Primary completion:** 2019-01-07
- **Final completion:** 2019-01-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416974, "Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01416974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*